T0	Participants 67 88	in pancreatic cancer:
T1	Participants 399 503	resectable pancreatic cancer patients treated with adjuvant gemcitabine compared with untreated patients
T2	Participants 632 644	observation.
T3	Participants 645 690	Tissue samples of 162 patients were available
T4	Participants 1418 1458	expression in pancreatic cancer patients